De PROMINENT-studie: zwanenzang van de fibraten

Thomas T. van Sloten; Fabrice M. A. C. Martens; Frank L. J. Visseren

De PROMINENT-studie: zwanenzang van de fibraten

Thomas T. van Sloten
, Fabrice M. A. C. Martens
, Frank L. J. Visseren

Research output: Contribution to journal › Article › Professional

Abstract

Post hoc analyses of previous fibrate trials have suggested that individuals with type 2 diabetes mellitus with high triglyceride levels and low HDL-cholesterol levels benefit from fibrate therapy even when the overall trial results were neutral. However the PROMINENT (Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes) trial seems to close the door for fibrates. The trial found that fibrates do not reduce the risk of cardiovascular disease among individuals with type 2 diabetes and high triglyceride levels and low HDL cholesterol levels, despite triglyceride lowering. The results of PROMINENT suggest that triglyceride lowering without decreases in the plasma concentration of atherogenic lipoproteins are unlikely to decrease the risk of cardiovascular disease. These results also highlight the importance of rigorously confirmation of post hoc findings before implementation in clinical practice.

Original language	Dutch
Journal	Nederlands tijdschrift voor geneeskunde
Volume	167
Publication status	Published - 5 Apr 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{abad7ab57fcd4ea2a348d0d2e90a68ee,

title = "De PROMINENT-studie: zwanenzang van de fibraten",

abstract = "Post hoc analyses of previous fibrate trials have suggested that individuals with type 2 diabetes mellitus with high triglyceride levels and low HDL-cholesterol levels benefit from fibrate therapy even when the overall trial results were neutral. However the PROMINENT (Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes) trial seems to close the door for fibrates. The trial found that fibrates do not reduce the risk of cardiovascular disease among individuals with type 2 diabetes and high triglyceride levels and low HDL cholesterol levels, despite triglyceride lowering. The results of PROMINENT suggest that triglyceride lowering without decreases in the plasma concentration of atherogenic lipoproteins are unlikely to decrease the risk of cardiovascular disease. These results also highlight the importance of rigorously confirmation of post hoc findings before implementation in clinical practice.",

author = "\{van Sloten\}, \{Thomas T.\} and Martens, \{Fabrice M. A. C.\} and Visseren, \{Frank L. J.\}",

year = "2023",

month = apr,

day = "5",

language = "Dutch",

volume = "167",

journal = "Nederlands tijdschrift voor geneeskunde",

issn = "0028-2162",

publisher = "Bohn Stafleu Van Loghum",

}

TY - JOUR

T1 - De PROMINENT-studie

T2 - zwanenzang van de fibraten

AU - van Sloten, Thomas T.

AU - Martens, Fabrice M. A. C.

AU - Visseren, Frank L. J.

PY - 2023/4/5

Y1 - 2023/4/5

N2 - Post hoc analyses of previous fibrate trials have suggested that individuals with type 2 diabetes mellitus with high triglyceride levels and low HDL-cholesterol levels benefit from fibrate therapy even when the overall trial results were neutral. However the PROMINENT (Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes) trial seems to close the door for fibrates. The trial found that fibrates do not reduce the risk of cardiovascular disease among individuals with type 2 diabetes and high triglyceride levels and low HDL cholesterol levels, despite triglyceride lowering. The results of PROMINENT suggest that triglyceride lowering without decreases in the plasma concentration of atherogenic lipoproteins are unlikely to decrease the risk of cardiovascular disease. These results also highlight the importance of rigorously confirmation of post hoc findings before implementation in clinical practice.

AB - Post hoc analyses of previous fibrate trials have suggested that individuals with type 2 diabetes mellitus with high triglyceride levels and low HDL-cholesterol levels benefit from fibrate therapy even when the overall trial results were neutral. However the PROMINENT (Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes) trial seems to close the door for fibrates. The trial found that fibrates do not reduce the risk of cardiovascular disease among individuals with type 2 diabetes and high triglyceride levels and low HDL cholesterol levels, despite triglyceride lowering. The results of PROMINENT suggest that triglyceride lowering without decreases in the plasma concentration of atherogenic lipoproteins are unlikely to decrease the risk of cardiovascular disease. These results also highlight the importance of rigorously confirmation of post hoc findings before implementation in clinical practice.

UR - https://www.scopus.com/pages/publications/85151782455

M3 - Article

C2 - 37022121

SN - 0028-2162

VL - 167

JO - Nederlands tijdschrift voor geneeskunde

JF - Nederlands tijdschrift voor geneeskunde

ER -

De PROMINENT-studie: zwanenzang van de fibraten

Abstract

UN SDGs

Other files and links

Cite this